Microba Life Sciences Limited · ASX:MAP
Microba Life Sciences — Q4 FY22 Earnings Presentation
26 slides from Microba Life Sciences's earnings presentation, Jul 20, 2022
Slide 1: Investor Update Q4 FY22 Results
or personal use only Investor Update Q4 FY22 Results July 2022 Authorised for release by the Board
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Microba Life Sciences Limited (Microba). Summary information - This Presentation contains summary information about Microba and its activities which is current only as at the date of this Presentation, being 20 July 2022. Microba may i
Slide 3: Company Snapshot
Company Snapshot or personal use only Continuous YoY Partnerships with market leaders Large, unique, proprietary revenue growth over incl. SYNLAB (GR:SYAB), microbiome databank 5 years of operations Illumina (NASDAQ: ILMN), Genova Diagnostics, and G42 3 key therapeutic programs World-leading technol
Slide 4: Q4 FY22 Financial Highlights
Q4 FY22 Financial Highlights (All figures in AU$) or personal use only 59% 25% growth on PCP growth YoY QTR Revenue FY Revenue Q4 FY22 revenue totalled $1.86m, FY22 unaudited revenue totalled $4.69m, a record result another year of positive growth 4
Slide 5: Q4 FY22 Testing Services - Key milestones
or personal use only Q4 FY22 Testing Services - Key milestones 5
Slide 6: Testing Services - Key Q4 FY22 Milestones
Testing Services - Key Q4 FY22 Milestones or personal use only USA OPERATIONS GCC OPERATIONS COMMENCED COMMENCED Distribution partnership Distribution partnership to open US Healthcare to open Middle East market commenced market commenced NEW PRODUCT PARTNERSHIP LAUNCHED SIGNED Next generation Partn
Slide 7: New strategic partnership to deliver consumer health service
New strategic partnership to deliver consumer health service or personal use only • Strategic partnership with nib-backed digital healthcare company Midnight Health • Subscription model • Personalised supplements delivered monthly based on microbiome test results – delivered with trained, registered
Slide 8: Expanding network of global distribution partners
Expanding network of global distribution partners Distribution agreements executed with global market leaders to distribute microbiome testing solutions powered by Microba’s world leading Analysis Platform technology. or personal use only Update kit Update kit AU & NZ Europe US Middle East AU New Ne
Slide 9: Q4 FY22 Therapeutics - Key milestones
or personal use only Q4 FY22 Therapeutics - Key milestones 9
Slide 10: Therapeutics - Key Q4 FY22 Milestones
Therapeutics - Key Q4 FY22 Milestones or personal use only Inflammatory Bowel Disease Cancer Immunotherapy Autoimmune Diseases PROGRESSING TO PHASE I LEADS DISCOVERED COMMENCED IBD program lead candidate Cancer program accelerated, Autoimmune program with MAP315 progressed in ahead of schedule with
Slide 11: Inflammatory Bowel Disease program – MAP315
Inflammatory Bowel Disease program – MAP 315 Addressing a key gap in existing therapy for UC sufferers or personal use only Ulcerative Colitis Addressable Ulcerative Colitis Therapeutic Patient Population1 Global Market Size2 MAP315 has the potential to (% of total) Mild Moderate Severe ($USD Billio
Slide 12: IBD program – MAP315: Rapidly progressing to Phase I
Inflammatory Bowel Disease program – MAP315 Rapidly progressing to Phase I or personal use only Completed Ongoing Upcoming In vivo efficacy Immunomodulation Mechanism of Action IBD UC Gut barrier integrity Data Driven UC Clinical Studies Identification MAP 315 Manufacturability cGMP Clinical Suppl
Slide 13: IFF Allergy Treatment Partnership
IFF (NYSE: IFF) Allergy Treatment Partnership Discovering novel microbiome treatments for allergies or personal use only • International Flavors & Fragrances Inc. (NYSE: IFF), $29B1 market cap • Industry leader in food, beverage, health, biosciences • Major global probiotics supplier Allergy Treatme
Slide 14: Outlook
or personal use only Outlook 14
Slide 15: Outlook
Outlook or personal use only Global testing • Driving sales growth with recently commenced partnerships services growth • Expansion through onboarding new partnerships • Advancing the company’s key therapeutic programs Therapeutic • Moving lead MAP315 asset into the clinic advancement • Progressing
Slide 16: Appendix: Microba Overview
or personal use only Appendix Microba Overview 16
Slide 17: Microba's Commercial Model
Microba’s Commercial Model Global testing services build a proprietary databank driving transformative novel therapies or personal use only Services Databank Therapeutics Proprietary databank Data Insights Health Data Customer Novel Testing Biome Data Therapies Microba provides testing Data-driven t
Slide 18: Microba Technology
Other Microba Technology Technology World-leading or personal use only microbiome analysis technology unlocks routine testing and microbiome therapies up to 95% coverage1 up to 34x more accurate2 Published in 1 Calculated by analysing more than 10k samples across Microba’s databank Illustrative visu
Slide 19: The gut microbiome plays a key role in health & disease
The gut microbiome plays a key role in health & disease or personal use only What is the gut microbiome? Modifying the The community of microorganisms that inhabit gut microbiome; the lower digestive tract containing trillions of microbial cells known as the gut microbiome. a key missing piece to re
Slide 20: Microbiome science is changing medicine
Microbiome science is changing medicine and will transform chronic disease management or personal use only Microbiome therapy to treat Microbiome testing to match patients chronic diseases with the right treatment Microbiome modulating primary and adjuvant Microbiome biomarkers and signatures are be
Slide 21: Large, unique, proprietary databank driving multiple therapeutic opportunities
Large, unique, proprietary databank driving multiple therapeutic opportunities or personal use only Revealing disease signatures Already producing novel therapeutic leads across 18 diseases Proprietary Depression Parkinson’s Disease Databank 18 16 Diseases 15K 1.2M 11.7M 13 13 samples genomes genes
Slide 22: Repeatable, scalable, data-driven platform discovering novel therapies
Repeatable, scalable, data-driven platform discovering novel monoclonal microbial cell therapies or personal use only Monoclonal Population Identify AI & Advanced Disease microbial testing groups Biostatistics Models drug lead Healthy Orally administered, healthy Disease human donor derived, monoclo
Slide 23: Repeatable human first, data-driven therapeutic platform
Repeatable human first, data-driven therapeutic platform Demonstrating rapid translation from data to first in human or personal use only CANDIDATE SELECTION PROCESS 25 bacteria 4,784 Bacteria observed Many bacteria differentially prioritised based in Microba dataset abundant in health vs IBD on sig
Slide 24: Board of Directors
Board of Directors or personal use only Pasquale Rombola Prof. Ian Frazer Dr Caroline Popper Prof Gene Tyson Dr Hyungtae Kim Richard Bund Chairman Deputy Chairman and Non-Executive Co-Founder, Non-Executive Director Non-Executive Director Non-Executive Director Chair Medical Advisory Board Director
Slide 25: Medical Advisory Board
Medical Advisory Board or personal use only Prof. Ian Frazer Dr Jakob Begun Dr Paul Griffin Dr Chris Hogan Prof Maria Abreu Prof Jean-Frederic Colombel Deputy Chairman and Medical Advisory Board, Medical Advisory Board, Medical Advisory Board, IBD Advisory Panel Member, IBD Advisory Panel Member, Ch
Slide 26: Contact
Contact or personal use only Dr Luke Reid Chief Executive Officer luke.reid@microba.com Head Office Level 10, 324 Queen Street Brisbane QLD Australia Pasquale Rombola Laboratory Princess Alexandra Hospital Chairman Woolloongabba QLD Australia pasquale.rombola@microba.com
Microba Life Sciences — Q4 FY22 Earnings Presentation on 6ix